❮ Back to Researchers

Jiwon Oh

MD, PhD

Scientist

Email: Jiwon.Oh@unityhealth.to
Tel: 416-864-6060 ext. 2282

Research Programs

Biography

Research Interests

Multiple sclerosis (MS), MRI biomarkers with clinical utility in prognostication and disease monitoring, cohort studies

Research Activities

Jiwon Oh is a staff neurologist, scientist, and Medical Director of the Barlo Multiple Sclerosis (MS) Program at St. Michael’s Hospital, University of Toronto. Dr. Oh’s research focuses on developing advanced MRI techniques in the spinal cord and brain for use in clinical settings. She leads the MRI research program at St. Michael’s Hospital, and is the principal investigator on numerous local and multi-center collaborative studies, including the Canadian Prospective Cohort Study to Understand Progression in MS (CanProCo), which is a national prospective cohort study designed to better understand progression in MS.

Recent Publications

  1. Petrin, J, Marrie, RA, Devonshire, V, Jichici, D, Hrebicek, O, Metz, LM et al.. Good multiple sclerosis (MS) care and how to get there in Canada: Perspectives of Canadian healthcare providers working with persons with MS. Front Neurol. 2023;14 :1101521. doi: 10.3389/fneur.2023.1101521. PubMed PMID:36937527 PubMed Central PMC10018146.
  2. Daruwalla, C, Shaygannejad, V, Ozakbas, S, Havrdova, EK, Horakova, D, Alroughani, R et al.. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. Mult Scler. 2023; :13524585231151951. doi: 10.1177/13524585231151951. PubMed PMID:36851894 .
  3. Freedman, DE, Oh, J, Feinstein, A. Neuropsychiatric Status of Patients With Multiple Sclerosis Across Disease Duration Intervals. J Neuropsychiatry Clin Neurosci. 2023; :appineuropsych20220124. doi: 10.1176/appi.neuropsych.20220124. PubMed PMID:36785945 .
  4. Tohyama, S, Oh, J, Timm, M, Cheng, JC, Halawani, A, Mikulis, DJ et al.. Should trigeminal neuralgia be considered a clinically isolated syndrome?. Mult Scler. 2023; :13524585221149886. doi: 10.1177/13524585221149886. PubMed PMID:36703283 .
  5. Khakban, A, Rodriguez Llorian, E, Michaux, KD, Patten, SB, Traboulsee, A, Oh, J et al.. Direct Health Care Costs Associated With Multiple Sclerosis: A Population-Based Cohort Study in British Columbia, Canada, 2001-2020. Neurology. 2023;100 (9):e899-e910. doi: 10.1212/WNL.0000000000201645. PubMed PMID:36450607 PubMed Central PMC9990437.
  6. Spelman, T, Ozakbas, S, Alroughani, R, Terzi, M, Hodgkinson, S, Laureys, G et al.. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry. Mult Scler. 2023;29 (2):221-235. doi: 10.1177/13524585221137502. PubMed PMID:36433775 PubMed Central PMC9925904.
  7. Kuhlmann, T, Moccia, M, Coetzee, T, Cohen, JA, Correale, J, Graves, J et al.. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023;22 (1):78-88. doi: 10.1016/S1474-4422(22)00289-7. PubMed PMID:36410373 .
  8. Oh, J, Bar-Or, A. Ublituximab: a new anti-CD20 agent for multiple sclerosis. Lancet Neurol. 2022;21 (12):1070-1072. doi: 10.1016/S1474-4422(22)00446-X. PubMed PMID:36402153 .
  9. Schneider, R, Oh, J. Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis. Curr Neurol Neurosci Rep. 2022;22 (11):721-734. doi: 10.1007/s11910-022-01229-z. PubMed PMID:36301434 PubMed Central PMC9607648.
  10. Seyman, E, Kim, D, Bharatha, A, Casserly, C, Krysko, K, Chantal, RH et al.. Quantitative spinal cord MRI and sexual dysfunction in multiple sclerosis. Mult Scler J Exp Transl Clin. 2022;8 (4):20552173221132170. doi: 10.1177/20552173221132170. PubMed PMID:36277232 PubMed Central PMC9585573.
Search PubMed

Affiliations & Other Activities

  • Staff Neurologist, Division of Neurology, Department of Medicine, St. Michael’s Hospital
  • Associate Professor, Department of Medicine, University of Toronto
  • Adjunct Faculty, Department of Neurology, Johns Hopkins University